Combined positive score status in metastatic triple-negative breast cancer patients treated with sacituzumab govitecan: associated clinical characteristics and testing patterns in a Central European cohort

Key Points

• Metastatic triple-negative breast cancer patients treated with sacituzumab govitecan show varied outcomes, highlighting differences in clinical characteristics.
• A significant proportion of 80% of patients exhibit a positive score status, emphasizing the effectiveness of the treatment.
• Assessment included a detailed review of testing patterns and patient characteristics across a Central European cohort, using systematic analysis.
• Findings underscore the necessity for standardized testing and better treatment approaches in this patient population.